Synergism of irbesartan and amlodipine on hemodynamic amelioration and organ protection in spontaneously hypertensive rats

Acta Pharmacologica Sinica

Volumn 32, Issue 9, 2011, Pages 1109-1115

  Shang, Wen ^a   Han, Ping ^a,c   Yang, Cheng Bing ^a,b   Gu, Xiao Wen ^a   Zhang, Wei ^a   Xu, Li Ping ^a   Fu, Shou Ting ^a,b   Su, Ding Feng ^a   Xie, He Hui ^a  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b SHENYANG PHARMACEUTICAL UNIVERSITY   (China)

^c SHENZHEN CENTER FOR DISEASE CONTROL AND PREVENTION   (China)

Author keywords

amlodipine; baroreflex sensitivity; blood pressure variability; end organ damage; hypertension; irbesartan; spontaneously hypertensive rats (SHR)

Indexed keywords

AMLODIPINE; IRBESARTAN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD PRESSURE; BLOOD PRESSURE VARIABILITY; CONTROLLED STUDY; DRUG POTENTIATION; ESSENTIAL HYPERTENSION; HEART LEFT VENTRICLE HYPERTROPHY; HEMODYNAMICS; KIDNEY INJURY; LOW DRUG DOSE; MALE; MONOTHERAPY; NONHUMAN; PRESSORECEPTOR REFLEX; RAT; SYSTOLIC BLOOD PRESSURE;

AMLODIPINE; ANIMALS; ANTIHYPERTENSIVE AGENTS; BAROREFLEX; BIPHENYL COMPOUNDS; BLOOD PRESSURE; DRUG SYNERGISM; HEMODYNAMICS; HYPERTENSION; HYPERTROPHY, LEFT VENTRICULAR; MALE; RATS; RATS, INBRED SHR; TETRAZOLES;

EID: 80052467930     PISSN: 16714083     EISSN: 17457254     Source Type: Journal    
DOI: 10.1038/aps.2011.88     Document Type: Article

References (37)

1. Kikuya M, Hozawa A, Ohokubo T, Tsuji I, Michimata M, Matsubara M, et al. Prognostic significance of blood pressure and heart rate variabilities: the Ohasama study. Hypertension 2000; 36: 901-6.
2. Parati G, Mancia G. Blood pressure variability as a risk factor Blood Press Monit 2001; 6: 341-7. (Pubitemid 34194891)
3. Su DF, Miao CY. Reduction of blood pressure variability: a new strategy for the treatment of hypertension. Trends Pharmacol Sc 2005; 26: 388-90
4. Su DF, Miao CY. Functional studies of arterial barorefex function in conscious rats. Acta Pharmacol Sin 2002; 23: 673-9
5. Sleight P. The importance of autonomic nervous system in health and disease. Aust N Z J Med 1997; 27: 467-73
6. Liu JG, Xu LP, Chu ZX, Miao CY, Su DF. Contribution of blood pressure variability to the effect of nitrendipine on end-organ damage in spontaneously hypertensive rats. J Hypertens 2003; 21: 1961-7.
7. Gupta AK, Arshad S, Poulter NR. Compliance, safety, and effec-tiveness of fixed-dose combinations of antihypertensive agents: a meta-analysis. Hypertension 2010; 55: 399-407
8. Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on Prevention Detection, Evaluation, and Treatment of High Blood Pressure. Hyper-ten sion 2003; 42: 1206-52 (Pubitemid 37553153)
9. Xie HH, Miao CY, Liu JG, Su DF. Effects of long-term treatment with candesartan on organ damages in sinoaortic denervated rats. J Cardio vasc Pharmacol 2003; 41: 325-31
10. Norman RA Jr, Coleman TG, Dent AC Continuous monitoring of arterial pressure indicates sinoaortic denervated rats are not hyper-ten sive. Hypertension 1981; 3: 119-25. (Pubitemid 11186248)
11. Smyth HS, Sleight P, Pickering GW. Reflex regulation of arteria pressure during sleep in man: a quantitative method of assessing barorefex sensitivity Circ Res 1969; 24: 109-21.
12. Su DF, Chen L, Kong XB, Cheng Y. Determination of arterial barorefex-blood pressure control in conscious rats. Acta Pharmacol Sin 2002 23: 103-9. (Pubitemid 34123320)
13. Xie HH, Miao CY, Jiang YY, Su DF. Synergism of atenolol and nitrendipine on hemodynamic amelioration and organ protection in hyper tensive rats. J Hypertens 2005; 23: 193-201.
14. Hayakawa H, Raij L. The link among nitric oxide synthase activity endothelial function, and aortic and ventricular hypertrophy in hypertension. Hypertension 1997; 29: 235-41 (Pubitemid 27074049)
15. Miao CY, Tao X, Gong K, Zhang SH, Chu ZX, Su DF. Aterial remodeling in chronic sinoaortic-denervated rats. J Cardiovasc Pharmacol 2001 37: 6-15. (Pubitemid 32012928)
16. Kimula K, Tojo A, Matsuoka H, Sugimoto T. Renel arteriolar diameters in spontaneously hypertensive rats: Vascular cast study Hypertension 1991; 18: 101-10.
17. Jin ZJ. About the evaluation of drug combination. Acta Pharmacol Sin 2004; 25: 146-7.
18. Su DF, Xu LP, Miao CY, Xie HH, Shen FM, Jiang YY Two useful methods for evaluating antihypertensive drugs in conscious freely moving rats Acta Pharmacol Sin 2004; 25: 148-51.
19. Waeber B, Ruilope LM. Amlodipine and valsartan as components of a rational and effective fxed-dose combination. Vasc Health Risk Manag 2009; 5: 165-74
20. Luft FC, Aronoff GR, Sloan RS, Fineberg NS, Weinberger MH. Calcium channel blockade with nitrendipine. Effects on sodium homeostasis the renin-angiotensin system, and the sympathetic nervous system in humans. Hypertension 1985; 7: 438-42 (Pubitemid 15021185)
21. Gennari C, Nami R, Pavese G, Gragnani S, Bianchini C, Buracchi P. Calcium-channel blockade (nitrendipine) in combination with ACE nhibition (captopril) in the treatment of mild to moderate hyper tension. Cardiovasc Drugs Ther 1989; 3: 319-25 (Pubitemid 19220412)
22. Parati G, Pomidossi G, Albini F, Malaspina D, Mancia G. Relationship of 24-hour blood pressure mean and variability to severity of target organ damage in hypertension. J Hypertens 1987; 5: 93-8 (Pubitemid 17058039)
23. Mancia G, Omboni S, Parati G. The importance of blood pressure variability in hypertension. Blood Press Monit 2000; 5: S9-S15 (Pubitemid 30428085)
24. Sander D, Kukla C, Klingelhofer J, Winbeck K, Conrad B. Relationship between circadian blood pressure patterns and progression of early carotid atherosclerosis: A 3-year follow-up study. Circulation 2000 102: 1536-41
25. Miao CY, Su DF. The importance of blood pressure variability in rat aortic and left ventricular hypertrophy by sinoaortic denervation. J Hypertens 2002; 20: 1865-72
26. Parati G, Lantelme P. Blood pressure variability target organ damage and cardiovascular events. J Hypertens 2002; 20: 1725-9
27. Bristow JD, Honour AJ, Pickering GW, Sleight P, Smyth HS. Diminished barorefex sensitivity in high blood pressure. Circulation 1969; 39: 48-54
28. La Rovere MT, Bigger JT Jr, Marcus FI, Mortara A, Schwartz PJ. Baro-refex sensitivity and heart-rate variability in prediction of total cardiac mortality after myocardial infarction. ATRAMI (Autonomic Tone and Refexes After Myocardial Infarction) Investigators. Lancet 1998; 351: 478-84 (Pubitemid 28070094)
29. Mortara A, La Rovere MT, Pinna GD, Prpa A, Maestri R, Febo O, et al. Arterial barorefex modulation of heart rate in chronic heart failure: clinical and hemodynamic correlates and prognostic implications Circulation 1997; 96: 3450-8 (Pubitemid 27513419)
30. Cai GJ, Miao CY, Xie HH, Lu LH, Su DF. Arterial barorefex dysfunction promotes atherosclerosis in rats. Atherosclerosis 2005; 183: 41-7.
31. Shan ZZ, Dai SM, Su DF. Relationship between baroreceptor refex function and end-organ damage in spontaneously hypertensive rats Am J Physiol 1999; 277: H1200-6
32. Parmer RJ, Cervenka JH, Stone RA. Barorefex sensitivity and heredity in essential hypertension. Circulation 1992; 85: 497-503
33. Parmer RJ, Cervenka JH, Stone RA, O'Connor DT. Autonomic func tion in hypertension: Are there racial difference? Circulation 1990; 81: 1305-11. (Pubitemid 20119629)
34. Brown AM. Receptors under pressure. An update on baroreceptors Circ Res 1980; 46: 1-10. (Pubitemid 10199432)
35. Matsumura K, Averill DB, Ferrario CM. Angiotensin II acts at AT1 receptors in the nucleus of the solitary tract to attenuate the baro-receptor refex. Am J Physiol 1998; 275: R1611-9.
36. 1 receptor antagonism and protection against cardiovascular end-organ damage. J Human Hypertens 1998 12: 301-9. (Pubitemid 28274360)
37. Murayama S, Hirano T, Sakaue T, Okada K, Ikejiri R, Adachi M. Low-dose candesartan cilexetil prevents early kidney damage in type 2 diabetic patients with mildly elevated blood pressure. Hypertens Res 2003; 26: 453-8 (Pubitemid 36849726)